MA32485B1 - Derives de pyridazine en tant qu'inhibiteurs de smo - Google Patents

Derives de pyridazine en tant qu'inhibiteurs de smo

Info

Publication number
MA32485B1
MA32485B1 MA33529A MA33529A MA32485B1 MA 32485 B1 MA32485 B1 MA 32485B1 MA 33529 A MA33529 A MA 33529A MA 33529 A MA33529 A MA 33529A MA 32485 B1 MA32485 B1 MA 32485B1
Authority
MA
Morocco
Prior art keywords
tumor
hedgehog
smo
inhibiting
pyridazine derivatives
Prior art date
Application number
MA33529A
Other languages
Arabic (ar)
English (en)
Inventor
Feng He
Stefan Peukert
Karen Miller-Moslin
Naeem Yusuff
Zhuoliang Chen
Bharat Lagu
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41130287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32485(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA32485B1 publication Critical patent/MA32485B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention porte d'une manière générale sur de nouveaux composés se rapportant au diagnostic et au traitement de pathologies concernant la voie hedgehog incluant, mais sans que ceci soit limitatif, la formation tumorale, le cancer, la néoplasie et les troubles hyperprolifératifs non malins. La présente invention concerne de nouveaux composés, de nouvelles compositions, des procédés pour leur utilisation et des procédés pour leur fabrication, de tels composés étant généralement pharmacologiquement utiles en tant qu'agents dans des thérapies dont le mécanismes d'action met en jeu des procédés d'inhibition de la genèse tumorale, la croissance tumorale et la survie tumorale à l'aide d'agents qui inhibent la voie de signalisation hedgehog et smo.
MA33529A 2008-07-18 2011-01-14 Derives de pyridazine en tant qu'inhibiteurs de smo MA32485B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8190008P 2008-07-18 2008-07-18
PCT/EP2009/059138 WO2010007120A1 (fr) 2008-07-18 2009-07-16 Dérivés de pyridazine en tant qu’inhibiteurs de smo

Publications (1)

Publication Number Publication Date
MA32485B1 true MA32485B1 (fr) 2011-07-03

Family

ID=41130287

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33529A MA32485B1 (fr) 2008-07-18 2011-01-14 Derives de pyridazine en tant qu'inhibiteurs de smo

Country Status (44)

Country Link
US (3) US20100041663A1 (fr)
EP (1) EP2318389B1 (fr)
JP (1) JP5492202B2 (fr)
KR (1) KR101312122B1 (fr)
CN (1) CN102143958B (fr)
AR (1) AR072816A1 (fr)
AU (1) AU2009272719B2 (fr)
BR (1) BRPI0916375A2 (fr)
CA (1) CA2731130C (fr)
CL (1) CL2011000101A1 (fr)
CO (1) CO6351727A2 (fr)
CR (1) CR20110014A (fr)
CU (1) CU24027B1 (fr)
CY (1) CY1114478T1 (fr)
DK (1) DK2318389T3 (fr)
DO (1) DOP2011000020A (fr)
EA (1) EA020710B1 (fr)
EC (1) ECSP11010764A (fr)
ES (1) ES2428100T3 (fr)
GE (1) GEP20125624B (fr)
GT (1) GT201100017A (fr)
HK (1) HK1155736A1 (fr)
HN (1) HN2011000193A (fr)
HR (1) HRP20130843T1 (fr)
IL (1) IL210494A (fr)
JO (1) JO2843B1 (fr)
MA (1) MA32485B1 (fr)
ME (1) ME01290B (fr)
MX (1) MX2011000721A (fr)
MY (1) MY149716A (fr)
NI (1) NI201100022A (fr)
NZ (1) NZ590483A (fr)
PE (1) PE20110153A1 (fr)
PL (1) PL2318389T3 (fr)
PT (1) PT2318389E (fr)
RS (1) RS52934B (fr)
SI (1) SI2318389T1 (fr)
SM (1) SMT201300114T1 (fr)
SV (1) SV2011003812A (fr)
TW (1) TWI431001B (fr)
UA (1) UA105181C2 (fr)
UY (1) UY31991A (fr)
WO (1) WO2010007120A1 (fr)
ZA (1) ZA201100205B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
EP2294061A2 (fr) 2008-04-29 2011-03-16 Eli Lilly & Company Antagonistes de la voie de la protéine hedgehog de phtalazine disubstituée
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
WO2010013849A1 (fr) * 2008-08-01 2010-02-04 日本ケミファ株式会社 Agoniste de gpr119
EP2617414A3 (fr) * 2008-10-01 2013-11-06 Novartis AG Antagonisme lissé pour le traitement de troubles liés à la voie Hedgehog
AU2009320251C1 (en) 2008-11-03 2013-08-15 Eli Lilly And Company Disubstituted phthalazine Hedgehog pathway antagonists
CN102216292B (zh) 2008-11-17 2014-08-13 伊莱利利公司 四取代的哒嗪hedgehog途径拮抗剂
PL2358698T3 (pl) 2008-11-17 2013-01-31 Lilly Co Eli Czteropodstawione pirydazyny jako antagoniści szlaku HEDGEHOG
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
NZ599964A (en) * 2009-11-18 2014-08-29 Novartis Ag Methods and compositions for treating solid tumors and other malignancies
JP5791150B2 (ja) 2009-12-15 2015-10-07 塩野義製薬株式会社 血管内皮リパーゼ阻害活性を有するオキサジアゾール誘導体
WO2011130500A1 (fr) 2010-04-16 2011-10-20 Novartis Ag Formulations d'une pyridazine bipyrazinyl
MX2012013130A (es) 2010-05-13 2013-04-11 Amgen Inc Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10.
ES2742261T3 (es) 2011-04-15 2020-02-13 Hivih Inhibidores de la replicación viral, su proceso de preparación y sus usos terapéuticos
RU2602185C2 (ru) 2011-06-02 2016-11-10 Новартис Аг Биомаркеры для терапии на основе ингибитора hedgehog
SG11201502137YA (en) * 2012-09-21 2015-04-29 Agency Science Tech & Res A method for treating a disease or disorder of the lung by inhibition of the hedgehog pathway
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
EP2821104A1 (fr) 2013-07-05 2015-01-07 Laboratoire Biodim Inhibiteurs de la réplication virale, leur procédé de préparation et leurs utilisations thérapeutiques
DK3092236T3 (en) * 2014-01-06 2020-11-30 Rhizen Pharmaceuticals S A Nye glutaminaseinhibitorer
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
TWI777174B (zh) 2014-03-14 2022-09-11 瑞士商諾華公司 針對lag-3之抗體分子及其用途
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CN114920840A (zh) 2014-10-14 2022-08-19 诺华股份有限公司 针对pd-l1的抗体分子及其用途
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
US10449211B2 (en) 2015-03-10 2019-10-22 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”—dependent signalling
AU2016271468B2 (en) 2015-06-04 2020-01-02 Sol-Gel Technologies Ltd. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
EP3964528A1 (fr) 2015-07-29 2022-03-09 Novartis AG Polythérapies comprenant des molécules d'anticorps dirigées contre lag-3
EP3878465A1 (fr) 2015-07-29 2021-09-15 Novartis AG Polythérapies comprenant des molécules d'anticorps tim-3
AU2016348391A1 (en) 2015-11-03 2018-05-17 Janssen Biotech, Inc. Antibodies specifically binding TIM-3 and their uses
AU2016369537B2 (en) 2015-12-17 2024-03-14 Novartis Ag Antibody molecules to PD-1 and uses thereof
CN109561680B (zh) * 2016-06-23 2021-07-13 圣朱德儿童研究医院 泛酸激酶的小分子调节剂
WO2018009466A1 (fr) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Composés dinucléotidiques cycliques d'acide nucléique bloqué et leurs utilisations
US10548908B2 (en) 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN106831718B (zh) * 2016-12-30 2019-05-07 上海科技大学 平滑受体配体及其应用
BR112019020877A2 (pt) * 2017-04-05 2020-05-12 Bayer Cropscience Aktiengesellschaft Derivados de 2-amino-5-oxialquil-pirimidina e seu uso para controlar o crescimento de plantas indesejadas
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
EP3642240A1 (fr) 2017-06-22 2020-04-29 Novartis AG Molécules d'anticorps dirigées contre cd73 et utilisations correspondantes
WO2019133632A1 (fr) 2017-12-27 2019-07-04 St. Jude Children's Research Hospital Méthodes de traitement de troubles associés à castor
SG11202006047RA (en) 2017-12-27 2020-07-29 St Jude Childrens Res Hospital Inc Small molecule modulators of pantothenate kinases
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
EP4031578A1 (fr) 2019-09-18 2022-07-27 Novartis AG Anticorps d'entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
CN114042069A (zh) * 2021-10-22 2022-02-15 陕西国际商贸学院 一种5-取代哒嗪-4-胺衍生物、制备方法和用途
WO2023101438A1 (fr) * 2021-11-30 2023-06-08 주식회사 헤지호그 Anticorps humain contre smo

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
US3668207A (en) * 1970-01-22 1972-06-06 Ciba Geigy Corp 2-amino-4-aryl-quinolines
DE2643753A1 (de) 1976-09-29 1978-04-06 Thomae Gmbh Dr K Neue 1h-pyrazolo eckige klammer auf 3,4-b eckige klammer zu pyridine
FR2421900A1 (fr) 1977-03-17 1979-11-02 Sauba Lab Piperazino-3-indoles, leur procede de preparation et leurs applications therapeutiques
FI70411C (fi) * 1980-12-29 1986-09-19 Pfizer Foerfarande foer framstaellning av nya antihypertensiva 4-amino-6,7-dimetoxi-2-piperazinokinazolin derivat
US5001125A (en) 1984-03-26 1991-03-19 Janssen Pharmaceutica N.V. Anti-virally active pyridazinamines
US4569934A (en) * 1984-10-09 1986-02-11 American Cyanamid Company Imidazo[1,2-b]pyridazines
CA1307786C (fr) * 1984-12-14 1992-09-22 Keiichi Yokoyama Derives quinazoline et preparations antihypertension contenant les memescomposes comme ingredients actifs
US4760064A (en) * 1984-12-18 1988-07-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
JP2544939B2 (ja) 1987-09-01 1996-10-16 大塚製薬株式会社 ベンゾヘテロ環誘導体
JPH0531271Y2 (fr) 1987-10-14 1993-08-11
JPH02193992A (ja) 1989-01-23 1990-07-31 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
JPH03106875A (ja) 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd １―（３―ピリジルメチル）フタラジン誘導体
ATE267174T1 (de) 1994-08-09 2004-06-15 Eisai Co Ltd Kondensierte pyridazinverbindungen
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5859012A (en) 1996-04-03 1999-01-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5935958A (en) * 1996-07-01 1999-08-10 Schering Corporation Muscarinic antagonists
WO1999054305A1 (fr) 1998-04-20 1999-10-28 Basf Aktiengesellschaft Amides substitues par voie heterocyclique et utilises comme inhibiteurs de calpaine
US6066636A (en) * 1998-06-30 2000-05-23 Schering Corporation Muscarinic antagonists
DE69919171T2 (de) 1998-06-30 2005-08-04 Schering Corp. Muskarin-rezeptor antagonisten
WO2000044376A1 (fr) 1999-01-28 2000-08-03 Bristol-Myers Squibb Company Composes antidepresseurs heterocycliques
JP2000281660A (ja) 1999-03-29 2000-10-10 Sumitomo Pharmaceut Co Ltd キナゾリン誘導体
ES2265929T3 (es) 1999-03-30 2007-03-01 Novartis Ag Derivados de ftalazina para el tratamiento de enfermedades inflamatorias.
BR0010304A (pt) 1999-05-04 2002-02-13 Schering Corp Derivados de piperazina úteis como antagonistas do ccr5
ES2165274B1 (es) 1999-06-04 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
AU780358B2 (en) 1999-06-08 2005-03-17 Lorantis Limited Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
FR2803593B1 (fr) * 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant
KR100830859B1 (ko) 2000-04-27 2008-05-21 아스텔라스세이야쿠 가부시키가이샤 이미다조피리딘 유도체 및 이를 함유하는 의약 조성물
DE10043659A1 (de) 2000-09-05 2002-03-14 Merck Patent Gmbh Arylpiperazinderivate
ES2172436B1 (es) 2000-10-31 2004-01-16 Almirall Prodesfarma Sa Derivados de indolilpiperidina como agentes antihistaminicos y antialergicos.
EP1353674A1 (fr) 2000-12-29 2003-10-22 Alteon, Inc. Methode de traitement du glaucome ivb
SE0103754L (sv) 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
AU2002247847A1 (en) 2001-04-09 2002-10-21 Lorantis Limited Therapeutic use and identification of modulators of a hedgehog signalling pathway or one of its target pathways
JP4929547B2 (ja) 2001-09-03 2012-05-09 コニカミノルタホールディングス株式会社 アゾメチン化合物、アゾメチン化合物と金属イオン含有化合物との混合物、感熱転写記録材料、カラートナー
ES2292812T3 (es) 2001-10-19 2008-03-16 Ortho-Mcneil Pharmaceutical, Inc. 2-fenil benzimidazol e imidazo-(4,5)-piridinas como inhibidores de cds1/chk2 y coadyuvantes para quimioterapia o radioterapia en el tratamiento del cancer.
BRPI0308696B8 (pt) * 2002-03-27 2021-05-25 Axovant Sciences Gmbh composto derivado de quinolina, seu processo de preparação, sua composição farmacêutica e seus usos
WO2003088970A2 (fr) 2002-04-22 2003-10-30 Johns Hopkins University School Of Medicine Modulateurs de voies de signalisation hedgehog, compositions et utilisations associees
PL378295A1 (pl) 2003-02-24 2006-03-20 Arena Pharmaceuticals, Inc. Podstawione pochodne arylowe i heteroarylowe jako modulatory metabolizmu glukozy oraz profilaktyka i leczenie zaburzeń tego metabolizmu
CN101712653A (zh) 2003-07-30 2010-05-26 泽农医药公司 哒嗪衍生物和它们作为治疗剂的用途
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
WO2005020897A2 (fr) 2003-08-22 2005-03-10 Dendreon Corporation Compositions et methodes permettant de traiter une maladie associee a l'expression de trp-p8
WO2005033288A2 (fr) 2003-09-29 2005-04-14 The Johns Hopkins University Antagonistes de la voie hedgehog
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
SI1789390T1 (sl) 2004-09-02 2012-05-31 Genentech Inc Piridilni inhibitorji hedgehog signalizacije
GB0422263D0 (en) * 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
DE102005023943A1 (de) 2005-05-20 2006-11-23 Grünenthal GmbH Pentafluorsulfanyl-substituierte Verbindung und deren Verwendung zur Herstellung von Arzneimitteln
CA2612227C (fr) * 2005-06-14 2014-04-22 Taigen Biotechnology Co., Ltd. Composes pyrimidine
US8364148B2 (en) * 2005-07-07 2013-01-29 Qualcomm Incorporated Methods and devices for interworking of wireless wide area networks and wireless local area networks or wireless personal area networks
JO2769B1 (en) 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Rapid decomposition of physiologically antagonistic agents of the 2-dopamine receptor
CA2629814C (fr) * 2005-11-14 2013-12-31 Genentech, Inc. Inhibiteurs a base de bisamide du signal hedgehog
WO2007064797A2 (fr) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibiteurs de c-met et leurs utilisations
US8541406B2 (en) * 2006-02-07 2013-09-24 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases
TWI417095B (zh) * 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc １，４-二取代之３-氰基-吡啶酮衍生物及其作為ｍＧｌｕＲ２-受體之正向異位性調節劑之用途
CN101460482B (zh) 2006-03-21 2013-03-27 默沙东公司 具有cxcr3拮抗剂活性的杂环取代的吡啶化合物
US20100168120A1 (en) * 2006-04-28 2010-07-01 Neuromedix Inc. Salts of pyridazine compounds
EP1849781A1 (fr) * 2006-04-28 2007-10-31 Laboratorios del Dr. Esteve S.A. Dérivés de 3-Amino-4-hydroxy pyrrolidine, procédé de fabrication et utilisation come medicaments
WO2007127475A2 (fr) * 2006-04-28 2007-11-08 Northwestern University Compositions et traitements contre des maladies démyélinisantes et des troubles de type douleur
CN101754762A (zh) 2006-04-28 2010-06-23 西北大学 用于治疗神经炎症性疾病的包含哒嗪化合物的制剂
AR061975A1 (es) 2006-07-14 2008-08-10 Schering Corp Compuestos de piperazina 1,4-sustituida con actividad antagonista de cxcr3, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de quimioquina cxcr3
GB0623258D0 (en) * 2006-11-22 2007-01-03 Remynd Nv Thiadiazole derivatives for the treatment of neuro-degenerative diseases
MX2009006071A (es) 2006-12-14 2009-06-16 Syngenta Participations Ag 4-fenil-pirano-3,5-dionas,4-fenil-tiopirano-3,5-dionas y ciclohexanotrionas como herbicidas novedosos.
US20120157466A1 (en) * 2006-12-22 2012-06-21 Qingbei Zeng Heterocyclic compounds with cxcr3 antagonist activity
JO2849B1 (en) 2007-02-13 2015-03-15 جانسين فارماسوتيكا ان. في Dopamine 2 receptor antagonists are rapidly hydrolyzed
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
AR065622A1 (es) 2007-03-07 2009-06-17 Ortho Mcneil Janssen Pharm Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
JP5147866B2 (ja) 2007-03-15 2013-02-20 メルク・シャープ・アンド・ドーム・コーポレーション グルカン合成酵素阻害剤として有用であるピリダジノン誘導体
JP5550352B2 (ja) * 2007-03-15 2014-07-16 ノバルティス アーゲー 有機化合物およびその使用
EP2121579B1 (fr) 2007-03-15 2011-04-20 F. Hoffmann-La Roche AG Malonamides comme antagonistes des récepteurs de l'orexine
US8222251B2 (en) * 2007-09-07 2012-07-17 Amgen Inc. Pyridopyridazine compounds, compositions and methods of use
GB0808888D0 (en) * 2008-05-15 2008-06-25 Syngenta Participations Ag Insecticidal compounds
CA2729313C (fr) 2008-07-03 2016-08-30 Janssen Pharmaceutica Nv 6-(1-piperazinyl)-pyridazines substituees comme antagonistes du recepteur 5-ht<sb>6</sb>
US20100029655A1 (en) * 2008-07-11 2010-02-04 Martin Robert Leivers Processes For The Preparation Of Anti-Viral Compounds And Compositions Containing Them
CN102099339A (zh) 2008-07-18 2011-06-15 武田药品工业株式会社 苯并氮杂衍生物及其作为组胺h3拮抗剂的用途
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
JP2011528337A (ja) 2008-07-18 2011-11-17 サノフイ−アベンテイス 新規トリアゾロ［４，３−ａ］ピリジン誘導体、これらの調製方法、医薬としてのこれらの使用、医薬組成物および、特にｍｅｔ阻害剤としての、新規使用
TW201006839A (en) 2008-07-18 2010-02-16 Sanofi Aventis Novel imidazo[1,2-a]pyridine derivatives, process for the preparation thereof, use thereof as medicaments, pharmaceutical compositions and novel use, in particular as MET inhibitors
FR2933982A1 (fr) 2008-07-18 2010-01-22 Sanofi Aventis Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
US8216547B2 (en) 2008-07-18 2012-07-10 Janssen Pharmaceutica Nv Radiolabelled TRP M8 receptor ligands
WO2010017240A2 (fr) * 2008-08-04 2010-02-11 Amgen Inc. Modulateurs de kinase aurora et procédés d’utilisation
EP2617414A3 (fr) 2008-10-01 2013-11-06 Novartis AG Antagonisme lissé pour le traitement de troubles liés à la voie Hedgehog
AU2009320251C1 (en) * 2008-11-03 2013-08-15 Eli Lilly And Company Disubstituted phthalazine Hedgehog pathway antagonists
US7968128B2 (en) * 2008-11-03 2011-06-28 Viva Pharmaceutical Inc. Plant extract compositions for affecting sleep
CN102216292B (zh) * 2008-11-17 2014-08-13 伊莱利利公司 四取代的哒嗪hedgehog途径拮抗剂
FR2939134A1 (fr) * 2008-12-01 2010-06-04 Sanofi Aventis Derives de 6-cycloamino-3-(1h-pyrrolo°2,3-b!pyridin-4-yl) imidazo°1,2-b!-pyridazine, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
NI201100022A (es) 2011-08-05
DOP2011000020A (es) 2011-02-15
TW201008929A (en) 2010-03-01
CA2731130A1 (fr) 2010-01-21
AU2009272719A1 (en) 2010-01-21
CU20110011A7 (es) 2011-12-28
AU2009272719B2 (en) 2012-06-28
TWI431001B (zh) 2014-03-21
EA020710B1 (ru) 2015-01-30
CU24027B1 (es) 2014-08-28
ECSP11010764A (es) 2011-02-28
NZ590483A (en) 2012-07-27
WO2010007120A1 (fr) 2010-01-21
JP5492202B2 (ja) 2014-05-14
ME01290B (fr) 2013-06-20
US8481542B2 (en) 2013-07-09
DK2318389T3 (da) 2013-09-30
IL210494A0 (en) 2011-03-31
US20130261299A1 (en) 2013-10-03
SI2318389T1 (sl) 2013-10-30
SV2011003812A (es) 2011-07-05
UY31991A (es) 2010-02-26
PT2318389E (pt) 2013-09-20
CY1114478T1 (el) 2016-10-05
JO2843B1 (en) 2014-09-15
CL2011000101A1 (es) 2011-07-01
PE20110153A1 (es) 2011-03-14
GEP20125624B (en) 2012-08-27
HN2011000193A (es) 2014-06-09
CN102143958A (zh) 2011-08-03
MX2011000721A (es) 2011-02-24
CA2731130C (fr) 2016-03-29
HRP20130843T1 (en) 2013-10-11
ES2428100T3 (es) 2013-11-05
EP2318389A1 (fr) 2011-05-11
HK1155736A1 (en) 2012-05-25
EP2318389B1 (fr) 2013-06-19
MY149716A (en) 2013-10-14
SMT201300114T1 (it) 2013-11-08
AR072816A1 (es) 2010-09-22
KR101312122B1 (ko) 2013-09-26
US20120289507A1 (en) 2012-11-15
CR20110014A (es) 2011-08-26
UA105181C2 (uk) 2014-04-25
US9409871B2 (en) 2016-08-09
IL210494A (en) 2015-08-31
GT201100017A (es) 2013-08-29
KR20110036620A (ko) 2011-04-07
BRPI0916375A2 (pt) 2018-02-06
RS52934B (en) 2014-02-28
US20100041663A1 (en) 2010-02-18
CO6351727A2 (es) 2011-12-20
CN102143958B (zh) 2013-12-18
ZA201100205B (en) 2011-10-26
JP2011528329A (ja) 2011-11-17
EA201100192A1 (ru) 2011-08-30
PL2318389T3 (pl) 2013-11-29

Similar Documents

Publication Publication Date Title
MA32485B1 (fr) Derives de pyridazine en tant qu&#39;inhibiteurs de smo
MA34066B1 (fr) Composes de la pyrrolopyrimidine utilises en tant qu&#39;inhibiteurs des cdk4/6
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
EP4257591A3 (fr) Inhibiteur de la déméthylase-1 spécifique de la lysine
EA201200473A1 (ru) Замещенные (гетероарилметил)тиогидантоины
MX2010007714A (es) Piridinas fusionadas activas como inhibidores de c-met.
EP4275756A3 (fr) Dérivés de bipyrazole servant d&#39;inhibiteurs de jak
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
EA201070618A1 (ru) 4-пиразолил-n-арилпиримидин-2-амины и 4-пиразолил-n-гетероарилпиримидин-2-амины в качестве ингибиторов киназ janus
EA201400245A1 (ru) Ингибиторы dyrk1 и их применение
EA201290957A1 (ru) Пиразол-4-илгетероциклилкарбоксамидные соединения и способы их применения
WO2013016720A3 (fr) Nouveaux dérivés biaryl-hétérocycliques substitués en tant qu&#39;inhibiteurs de protéine kinase pour le traitement du cancer et d&#39;autres maladies
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
MA32137B1 (fr) Hétérocycles spirocycliques, médicaments contenant ces composés, leur utilisation et procédé pour leur fabrication
IN2015MN00002A (fr)
MX349550B (es) 1,7-diazacarbazoles y metodos de uso.
MX2010003269A (es) Derivados de pirrolotriazina utiles para tratar cancer a traves de la inhibicion de la aurora quinasa.
BRPI0917245B8 (pt) compostos derivados de isoquinolinona e sua composição farmacêutica
MY150054A (en) Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
EA201270347A1 (ru) Производные апогоссиполона в качестве противоопухолевых агентов
MX2014003455A (es) Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide.
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
TN2011000009A1 (en) Pyridazne derivatives as smo inhibitors
UA110978C2 (uk) Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak
UA112552C2 (uk) Гетероцикліламіни як інгібітори pi3k